← All trials
NCT03999723
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2019
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 28, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 182
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- Aarhus UniversityCollaborator
- University of OsloCollaborator
- University of GothenburgCollaborator
- Lund UniversityCollaborator
- Karolinska InstituteCollaborator
- University of Southern DenmarkCollaborator
- University of SussexCollaborator
- University of LeedsCollaborator
- University of CopenhagenCollaborator
- University of HelsinkiCollaborator
- University of CopenhagenCollaborator
- University of Southern CaliforniaCollaborator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenStudy chair
- University of CopenhagenSponsor investigator
- Van Andel Research InstituteCollaborator
- Technical University of DenmarkCollaborator
- Imperial College LondonCollaborator
- Aalborg UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.